Healthcare Equipment and Supplies
Company Overview of Neuronetics, Inc.
Neuronetics, Inc. develops and commercializes non-invasive therapy systems to treat chronic psychiatric and neurological disorders using MRI-strength magnetic field pulses. It offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. Its products are available upon the prescription of a psychiatrist. Neuronetics, Inc. was founded in 2001 and is headquartered in Malvern, Pennsylvania.
3222 Phoenixville Pike
Malvern, PA 19355-1245
Founded in 2001
Key Executives for Neuronetics, Inc.
Chief Executive Officer and President
Vice President of Product Development & Operations
Vice President of New Business Development
Compensation as of Fiscal Year 2014.
Neuronetics, Inc. Key Developments
Neuronetics, Inc. Appoints Christopher Thatcher as President and Chief Executive Officer
Dec 1 14
Neuronetics, Inc. announced that Christopher Thatcher has joined the company as President and Chief Executive Officer. Mr. Thatcher has two decades of experience in general management and operational leadership in growing and transforming companies. Most recently Mr. Thatcher led the Reichert Technology Global Business Unit of Ametek, Inc. as its Divisional Vice President and Business Unit Manager. In this role, Mr. Thatcher was responsible for revitalizing its brand and expanding the business globally to achieve exponential revenue growth.
Neuronetics, Inc.'s NeuroStar TMS Therapy(R) Shows Promise as Effective Once-Monthly Maintenance Therapy in Patients with Major Depressive Disorder
May 5 14
Neuronetics, Inc. announced results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(R) for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced remission in 61.2% of all enrolled patients. At three months, 62.5% of medication-free patients randomized to once-monthly treatment with NeuroStar TMS Therapy maintained response as compared to 43.8% of patients who did not receive maintenance treatment. The complete findings will be presented at the 167th American Psychiatric Association Annual Meeting in New York City. In the study, medication-free patients with a diagnosis of unipolar, non-psychotic MDD, who had failed to receive benefit from prior antidepressant medication, were treated with six weeks of NeuroStar TMS Therapy; patients who met response criteria were randomized to either once- monthly maintenance TMS treatments or monthly observation. Patients in either cohort could receive TMS reintroduction for protocol-defined symptomatic worsening. The primary outcome was the proportion of patients without symptomatic worsening throughout the three months of the maintenance treatment phase.
Neuronetics, Inc. Announces Results of Naturalistic, Observational Study from 42 Clinical Trial Sites in the United States
Sep 16 13
Neuronetics, Inc. announced that results of a naturalistic, observational study from 42 clinical trial sites in the United States, which examined the efficacy of acute treatment with NeuroStar TMS Therapy(R) in patients with Major Depressive Disorder (MDD), were published in the July 2013 issue of CNS Spectrums. In the study, patients who experienced persistent symptoms of MDD without benefit from concurrent antidepressant pharmacotherapy reported statistically and clinically meaningful improvement in quality of life (QOL) symptoms and functional status following acute treatment with NeuroStar TMS Therapy. Acute efficacy results of this trial were previously reported, showing statistically significant improvement from baseline in depression symptoms including 58% response and 37% remission rates as rated by the clinician using the CGI-Severity of Illness scale under conditions of general clinical use. MDD is a debilitating condition in which nearly two-thirds of patients do not benefit adequately from antidepressant medications, and continue to experience life-altering symptoms and functional impairment. At the end of the acute phase of NeuroStar TMS treatment, statistically significant improvements across physical health and mental health components variables were observed, as measured by the Short Form 36-Item Questionnaire (SF-36). Severely depressed patients experienced the most robust improvement in a relatively short time frame (six weeks). The larger treatment effects were observed on those subscale scores associated with improvements in mental health and social functioning. In addition, 37% (N=114) of study patients achieved remission during acute NeuroStar treatment and experienced a superior improvement in QOL compared with non-remitters. Patients with moderately severe to severe depression had the most robust improvement in QOL. The vitality, social functioning, role-emotional, and mental health perceptions subscales of SF-36 showed a statistically significant improvement of 12-14.8 points or 1.2-1.5 standard deviations (SDs) in the normed score. The mean mental component summary (MCS) score improved by 16.8 points to 33.5 (+/- 15.06), which is comparable to previous studies showing an improvement in the MCS scores following nine months of treatment with paroxetine (15.8), fluoxetine (15.1), or sertraline (17.4). The subpopulation of remitters showed a much more robust improvement of 27.4 to 30.9 points, reaching scores that are close to the general population norms and are only 0.13 to 0.55 SDs lower.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|